A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

NCT05394831 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR Mutant Advanced Non-small Cell Lung Cancer

Interventions

DRUG: JIN-A02

Sponsor

J Ints Bio